# US 2008/0306004 A1 · Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306004 A1
- Document ID: US20080306004A1
- Status: Published application
- Kind: A1
- Application number: 12/069,560
- Filed: 2008-02-11
- Published: 2008-12-11
- Earliest claimed: 2001-03-05
- Assignees: Nuvelo, Inc.
- Inventors: Y. Tom Tang
- Web page: https://patentgrep.com/patent/US20080306004A1

## CPC

- C12Q 1/6888: for detection or identification of organisms
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 14/475: Growth factors; Growth regulators
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 8, 10 and 12, or the mature protein coding portion thereof.

### Claim 2 (depends on 1)

An isolated polynucleotide encoding a polypeptide with biological activity, said polynucleotide having greater than about 99% sequence identity with the polynucleotide of claim 1.

### Claim 3 (depends on 1)

The polynucleotide of claim 1 which is a DNA sequence.

### Claim 4 (depends on 1)

An isolated polynucleotide which comprises the complement of the polynucleotide of claim 1.

### Claim 5

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 11, 13, and 15.

### Claim 6 (depends on 5)

A polynucleotide encoding a polypeptide according to claim 5.

### Claim 7 (depends on 1)

A nucleic acid array comprising the polynucleotide of claim 1 attached to a surface.

### Claim 8 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 9 (depends on 1)

An expression vector comprising the polynucleotide of claim 1.

### Claim 10 (depends on 1)

A host cell genetically engineered to express the polynucleotide of claim 1.

### Claim 11 (depends on 10)

The host cell of claim 10 wherein the polynucleotide is in operative association with a regulatory sequence that controls expression of the polynucleotide in the host cells.

### Claim 12 (depends on 5)

A composition comprising the polypeptide of claim 5 and a carrier.

### Claim 13 (depends on 5)

An antibody specific for the polypeptide according to claim 5.

### Claim 14 (depends on 1)

A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

### Claim 15 (depends on 1)

A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions; b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

### Claim 16 (depends on 16)

The method of claim 16, wherein the polynucleotide comprises an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

### Claim 17 (depends on 5)

A method for detecting the polypeptide of claim 5 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period of time sufficient to form the complex; and b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 5 is detected.

### Claim 18 (depends on 5)

A method for identifying a compound that binds to the polypeptide of claim 5, comprising: a) contacting the compound with the polypeptide of claim 5 under conditions and for a time sufficient to form a polypeptide/compound complex; and b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 5 is detected.

### Claim 19 (depends on 5)

A method for identifying a compound that binds to the polypeptide of claim 5 comprising: a) contacting the compound with the polypeptide of claim 5, in a cell, for a time sufficient to form a polypeptide/compound complex, wherein the complex directs expression of a reporter gene sequence in the cell; and b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 5 is identified.

### Claim 20 (depends on 5, 10)

A method of producing the polypeptide of claim 5, comprising: a) culturing the host cell of claim 10 under conditions sufficient to express the polypeptide of claim 5 in said cell; and b) isolating the polypeptide from the cell culture or cells of step (a).

### Claim 21 (depends on 5)

A kit comprising the polypeptide of claim 5.

### Claim 22 (depends on 5)

A method of treatment of a subject in need of enhanced activity or expression of the polypeptide of claim 5, comprising administering to the subject a composition selected from the group consisting of: a) a therapeutic amount of an agonist of said polypeptide; b) a therapeutic amount of said polypeptide; and c) a therapeutic amount of a polynucleotide encoding the polypeptide in a form and under conditions such that the polypeptide is produced, and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 5)

A method of treatment of a subject having need to inhibit activity or expression of the polypeptide of claim 5, comprising administering to the subject a composition selected from the group consisting of: a) a therapeutic amount of an antagonist to said polypeptide; b) a therapeutic amount of a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and c) a therapeutic amount of a polypeptide that competes with the peptide of claim 5, and a pharmaceutically acceptable carrier.
